Elad Gil

Elad Gil × Sarah Guo × Mark Zuckerberg × Priscilla Chan × Alex Rives

Biohub’s $500 million, 10- to 15-year commitment targets purpose-built biological data, combining frontier AI with wet labs from proteins to cells and whole systems.ESMfold predicted structures for more than 1.1 billion proteins and produced nanomolar binders from 96 synthesized designs without antibody-specific training, while open release could accelerate research but leaves biosafety and clinical translation unresolved.

Sarah Guo × Elad Gil

AI adoption is “blinding” among doctors, lawyers, and compliance teams, even as a weak Nvidia quarter could trigger panic; verticals such as coding, medical scribing, and legal software such as Harvey are consolidating.Monitor robotics timeline slippage and whether an AI IPO becomes a reflexive benchmark trade; Sarah forecasts somebody will make “hundreds of millions of dollars trading markets with LLMs” in 2026.

Daniel Nadler × Sarah Guo × Elad Gil

OpenEvidence says it became the default clinical-knowledge system for U.S. physicians within 18 months, reaching roughly 40% of doctors and about 20 times the usage of the next clinical decision-support platform.Its free, physician-focused distribution and semantic search across 35 million biomedical publications turn evidence retrieval into a scalable “curbside consult,” while exploding medical knowledge makes continuous decision support increasingly structural.

Sarah Guo × Elad Gil

AI leaders are emerging in foundation models, coding, medical scribing, and customer success, while sales productivity, financial-analyst tooling, accounting, and pharma remain open.The winning application playbook combines vertical workflows, proprietary data, distribution, and user-generated knowledge, while startup mergers may strengthen defense against incumbents; neglected fertility, longevity, and world-model opportunities remain constrained by financing, regulation, and uncertain commercialization.